Nkarta to present initial autoimmune data for NKX019
Nkarta flagged initial Phase 1/2 clinical readouts for CAR-NK therapy NKX019 across autoimmune diseases, with presentations scheduled for ACR Convergence 2026.
Data will be presented in November in Orlando, covering early signs of clinical activity in idiopathic inflammatory myopathy and systemic sclerosis.
A separate oral update will outline the overall safety profile across indications, including outcomes tied to the lymphodepletion regimen used before dosing.
The disclosures mark the first broad public look at NKX019’s autoimmune program, a key near-term catalyst for investor assessment.
NKTX•
